The BCR::ABL1 fusion, a well‐recognized high‐risk marker in ALL [3], was found in 7 of 170 patients: five with B‐Cell (3.3%) and two with mixed‐lineage immunophenotypes (Table S1). This evidence concerns the gene ABL1 and acute lymphoblastic leukemia.